A replay of the corporate presentation will be available on the Events section of the company’s investor relations website.

So far this MLB offseason, the reigning champion Dodgers have signed as many free agents as the rest of their division ...

A set of 5844 free MIT-licensed high-quality SVG icons for you to use in your web projects. Each icon is designed on a 24x24 grid and a 2px stroke. If you load an icon as an image, you can modify its ...

In 2024, for the first time since the Obama administration, the Houston Astros did not reach the ALCS. The end of that ...

While several of their midwest counterparts in the American League Central enjoyed a collective breakout in 2024, the quintet of National League clubs in the heartland had a far less encouraging ...

Chemical manufacturer Stardust Power Inc. announced that it broke ground on its $1.2 billion lithium refinery at the ...

Form GSTR-2A- Details of auto drafted supplies Form GSTR-2B- Auto drafted ITC statement Interestingly, both the above-referred statement reflects details of inward supplies as well as details of an ...

The state of Maryland is facing a $3 billion budget shortfall. Gov. Wes Moore has announced significant budget cuts and has said he will hike taxes on the wealthiest residents to increase ...

A total of P4.2 billion was appropriated for the new Senate building in the 2025 national budget, bringing the total allocation to the structure to P23.5 billion since 2018. In Mav Gonzales’ Wednesday ...

The GSTR-2B (input tax credit) statement will now be generated two days later on Thursday, January 16, from the originally scheduled date of January 14, for the December 2024 tax period.

Colossal Biosciences, the company that’s famously on a mission to bring back the woolly mammoth and two other extinct species, has raised a $200 million Series C at a $10.2 billion valuation ...

(NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced positive data from a Phase 2b clinical trial ...